Cargando…

Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507463/ https://www.ncbi.nlm.nih.gov/pubmed/37731635 http://dx.doi.org/10.3389/fonc.2023.1285219

Ejemplares similares

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma
por: Hu, Boyu, et al.
Publicado: (2018)

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas
por: Pan, Changqing, et al.
Publicado: (2021)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

CAR‐NK cell in cancer immunotherapy; A promising frontier
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
por: Hadiloo, Kaveh, et al.
Publicado: (2023)

Advances in CAR T cell immunotherapy for paediatric brain tumours
por: Rao, Padmashree, et al.
Publicado: (2022)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)

CAR-NK cells for cancer immunotherapy: from bench to bedside
por: Zhang, Leisheng, et al.
Publicado: (2022)

Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
por: Couto, Samuel C. F., et al.
Publicado: (2023)

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
por: Petersen, Christopher T., et al.
Publicado: (2019)

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies
por: Shatnyeva, Olga M., et al.
Publicado: (2015)

Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
por: Wang, Zong-Han, et al.
Publicado: (2023)

CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
por: Elmas, Ezgi, et al.
Publicado: (2022)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers
por: Dehbashi, Moein, et al.
Publicado: (2021)

Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
por: Hu, Zhiwei
Publicado: (2020)

The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues
por: Burns, Ian, et al.
Publicado: (2022)

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
por: Schmidt, Dayane, et al.
Publicado: (2022)

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
por: Luo, Hong, et al.
Publicado: (2019)

Heightened metabolic responses in NK cells from patients with neuroblastoma suggests increased potential for immunotherapy
por: Slattery, Karen, et al.
Publicado: (2022)

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
por: Cantoni, Claudia, et al.
Publicado: (2016)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma
por: Garofalo, Cinzia, et al.
Publicado: (2021)

NK cell-based tumor immunotherapy
por: Zhang, Hao, et al.
Publicado: (2023)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies
por: Dai, Xiaofeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f5uu9a9t0ert9dcfr9i574cn3b